Highest-materiality recent filing
Renalytix raises £11.6M in private placement and restructures $11.7M convertible bonds
Gross proceeds of £2.16M from first tranche (24M shares) and £9.43M from second tranche (104.7M shares) at £0.09 per share.
Renalytix launches £10M placing, restructures debt, plans Nasdaq delisting
Minimum £10M gross raised at 9p/share; first tranche of £2.1M closes Oct 9, second tranche conditional on shareholder vote.
Renalytix gets Nasdaq extension to Oct 25, 2024; transfers to Capital Market
Nasdaq Hearings Panel grants until October 25, 2024 to regain compliance with minimum bid price of $1.00.
Renalytix receives Nasdaq delisting notice; intends to appeal by June 28
Nasdaq determined company did not regain compliance with minimum bid price ($1.00) and MVLS ($50M) by June 19, 2024.
Medicare finalizes coverage for Renalytix's kidneyIntelX.dkd at $950/test effective Aug 1, 2024
Medicare issued final Local Coverage Determination (LCD) for kidneyIntelX.dkd; effective dates of service on/after August 1, 2024.
Renalytix Q3 revenue $0.5M; net loss $7.7M; strategic sale process initiated
Revenue of $0.5M, down from $0.7M YoY; net loss narrowed to $7.7M from $12.1M.
Renalytix enters $15M at-the-market equity offering with H.C. Wainwright
Company may sell ADSs with aggregate offering price up to $15M on Nasdaq through H.C. Wainwright.
Renalytix closes second tranche of private placement, raises ~$7M gross
Second Tranche of 26,815,841 ordinary shares at £0.20 each closed on April 24, 2024, following shareholder approval.
Renalytix president McLain resigns, Howard Doran appointed; equity offering expanded
Thomas McLain resigns as President effective April 30, 2024; severance includes 6 months base salary ($450K) and accelerated vesting of 12 months of options.
Renalytix raises $1M in registered direct offering at $0.375/share, with option for up to $3.9M
Issued 2,666,667 ordinary shares at $0.375 each for gross proceeds of approximately $1.0 million.
Renalytix raises ~$12M via two-tranche equity placing at £0.20/share
First tranche of 19,986,031 shares closes March 14, 2024, raising ~$5M gross.
Daniel Levangie, tendered his resignation from the Company's Board of Directors and all committees effective on October 31, 2024.
announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
announcing the appointment, on May 27, 2024, of Joel R. Jung as Interim Chief Financial Officer of the Company in connection with O. James Sterling’s resignation from his position with the Company.
On May 27, 2024, the board of directors (the “ Board ”) of the Company appointed Joel R. Jung as Interim Chief Financial Officer and designated Mr. Jung as the Company’s principal financial officer and principal accounting officer, effective as of May 28, 2024.
On May 24, 2024, O. James Sterling tendered his resignation from his position as the Chief Financial Officer of Renalytix plc (the “ Company ”).
On April 17, 2024, Thomas McLain notified the Company that he will resign as President of the Company, effective April 30, 2024
On April 23, 2024, the Company’s Board of Directors (the “ Board ”) appointed Howard Doran, currently the Company’s Chief Business Officer, to serve as the Company’s President, effective as of April 30, 2024.
Max materiality 1.00 · Median 0.55 · Most common event other_material